Key Points
- Amgen SVP Nancy Grygiel sold 2,970 shares for approximately $1.19 million, reducing her ownership by 28.81% to 7,340 shares.
- Amgen reported stronger-than-expected quarterly results, with $6.29 in adjusted EPS and $10.05 billion in revenue, up 9.5% year over year. The company issued fiscal 2026 EPS guidance of $22.30 to $23.50.
- The company declared a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 and a 2.5% yield, while analyst sentiment remained mixed with an overall “Hold” rating.
Amgen Inc. (NASDAQ:AMGN - Get Free Report) SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Amgen Stock Up 1.5%
AMGN opened at $410.95 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market capitalization of $221.79 billion, a price-to-earnings ratio of 25.54, a price-to-earnings-growth ratio of 3.77 and a beta of 0.41. The business has a 50-day moving average of $362.77 and a two-hundred day moving average of $356.24. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $418.40.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company's quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts expect that Amgen Inc. will post 22.73 earnings per share for the current year.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen's dividend payout ratio is 62.65%.
Key Headlines Impacting Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
- Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
- Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
- Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
- Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513
Institutional Investors Weigh In On Amgen
Several large investors have recently made changes to their positions in the business. Alpine Woods Capital Investors LLC raised its stake in shares of Amgen by 8.5% in the 2nd quarter. Alpine Woods Capital Investors LLC now owns 25,029 shares of the medical research company's stock valued at $9,064,000 after acquiring an additional 1,965 shares during the period. Aegis Wealth Management LLC purchased a new stake in Amgen during the 2nd quarter worth $783,000. Argyle Capital Partners LLC increased its holdings in Amgen by 5.5% in the 2nd quarter. Argyle Capital Partners LLC now owns 4,851 shares of the medical research company's stock valued at $1,756,000 after purchasing an additional 254 shares in the last quarter. Quent Capital LLC increased its holdings in Amgen by 2.1% in the 2nd quarter. Quent Capital LLC now owns 6,535 shares of the medical research company's stock valued at $2,366,000 after purchasing an additional 132 shares in the last quarter. Finally, Focused Alpha LLC increased its holdings in Amgen by 9.3% in the 2nd quarter. Focused Alpha LLC now owns 3,561 shares of the medical research company's stock valued at $1,289,000 after purchasing an additional 302 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Sanford C. Bernstein lifted their price target on shares of Amgen from $335.00 to $345.00 and gave the company a "market perform" rating in a report on Thursday. Piper Sandler reaffirmed an "overweight" rating on shares of Amgen in a research report on Friday, June 12th. Royal Bank Of Canada lifted their target price on Amgen from $370.00 to $400.00 and gave the company an "outperform" rating in a report on Wednesday. Weiss Ratings raised Amgen from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday. Finally, Erste Group Bank restated a "hold" rating on shares of Amgen in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $370.07.
View Our Latest Analysis on AMGN
About Amgen
(
Get Free Report)
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
